Re-engineering human GDNF as an IgG-GDNF fusion protein that penetrates the BBB via RMT can enable the future development of GDNF therapeutics for PD that are delivered to brain following non-invasive systemic administration. The gene discussed is GDNF; the disease is Parkinson disease.